Loading…
Tenderkart now works inside Claude and ChatGPT: search and analyse tenders right from your chat
Loading…
Ref. No.
Eligibility, documents, scope and key termsEligibility, required documents, scope of work and key terms of this tender, in one click.
| # | Schedule | Awardee / L1 Bidder | Status | Bids | Value |
|---|---|---|---|---|---|
| 1 | Schedule 5 | Savi Health ScienceLikely | Evaluation in Progress | 1 | ₹56,925 |
Tender Value
Refer Docs
EMD Value
Exempted
Closing Date
12 Sept 2024, 10:00 amClosed
Eligibility, documents, scope and key termsEligibility, required documents, scope of work and key terms of this tender, in one click.
Ondansetron Oral Liquid (Q2)
Gefitinib Tablet (Q2) Acyclovir Tablets (V2) (Q2)
Anti TB Drugs - Linezolid 600 mg Tablets (Q1) Tablets (V2) (Q2)
6848682
GEM/2024/B/5349119
Two Packet Bid
Ondansetron Oral Liquid,Gefitinib Tablet,Ondansetron Injection,Acyclovir Tablets (V2),Anti TB Drugs
Punjab; Jalandhar
Item wise evaluation
PRODUCT
7 documents required · 7 mandatory
3 yrs
₹31
80%
| Item | Delivery Location | Qty | Delivery |
|---|---|---|---|
| Ondansetron Oral Liquid (Q2) | - | - | - |
| Gefitinib Tablet (Q2) Acyclovir Tablets (V2) (Q2) | - | - | - |
| Anti TB Drugs - Linezolid 600 mg Tablets (Q1) Tablets (V2) (Q2) | - | - | - |
Exempted
12 Sept 2024
12 Sept 2024
12 Sept 2024
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_6848682.pdf
GEM_BID
technical-specifications-of-linezolid-600-mg-1_2022-02-07-14-28-52_c70bf82de51e36175078e84ca63e4b82.pdf
SPECIFICATION
ATC_91387234-3bc1-4fad-abbd1725249734321_DGLPOIC.docx
OTHER
list-of-categories-where-trials-are-allowed_1712126171.pdf
OTHER
gtc.pdf
OTHER
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .